<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy regimens for locally advanced, squamous cell carcinoma of the head and neck: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy (TAX323)&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy regimens for locally advanced, squamous cell carcinoma of the head and neck: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy (TAX323)<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy regimens for locally advanced, squamous cell carcinoma of the head and neck: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy (TAX323)<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> Every 21 days for four cycles.</td> </tr> <tr class="divider_bottom"> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose and route</td> <td class="subtitle1">Administration</td> <td class="subtitle1">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS* to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS* and administer over 60 minutes. Do not administer with aluminum needles or IV sets.</td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Fluorouracil (FU)</td> <td>750 mg/m<sup>2</sup>/day IV</td> <td>Dilute in 500 to 1000 mL D5W or NS* and administer as a continuous infusion over 24 hours.</td> <td>Days 1 through 5</td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Hydration</strong></td> <td colspan="4"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Additional hydration of 1 to 2 liters of NS on day 2 to prevent nephrotoxicity.</li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="4"> <ul> <li>HIGH (&gt;90% frequency of emesis).</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="4"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration.</li> <li>Refer to UpToDate topics on infusion reactions to systemic chemotherapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="4"> <ul> <li>In the original protocol, prophylactic therapy with a fluoroquinolone antibiotic was used on days 5 to 15 of each cycle because of the high frequency of grade 3 or 4 neutropenia.<sup>[1]</sup></li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="4"> <ul> <li>Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or kidney dysfunction</strong></td> <td colspan="4"> <ul> <li>Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 times the ULN with AP &gt;2.5 times the ULN.<sup>[2]</sup> Dose adjustments for FU may be needed for patients with hepatic impairment.<sup>[2]</sup> The optimal approach to cisplatin therapy in patients with preexisting kidney impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with kidney insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan="4"> <ul> <li>Caution is required if administering docetaxel with strong CYP3A4 inhibitors.<sup>¶</sup> According to the United States Prescribing Information, avoid the use of docetaxel with strong CYP3A4 inhibitors (if possible). If concomitant therapy cannot be avoided, monitor closely for toxicity and consider a docetaxel dose reduction.<sup>[2]</sup> Docetaxel dose reductions for concomitant therapies should be individualized based on patient factors (eg, performance status) and the intent of therapy (ie, curative or palliative). </li> <li>Refer to "Suggested dose modifications for toxicity" below.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>CBC, differential, and platelet count on day 1 on each cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Creatinine and electrolytes on day 5 or 6 of each treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Basic metabolic panel, including creatinine and electrolytes, and liver function tests prior to each treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for neurotoxicity, diarrhea, and palmar-plantar erythrodysesthesias prior to each treatment cycle.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Patients with kidney impairment, hyperuricemia, and bulky tumors are at risk for TLS and should undergo correction of dehydration and lowering of high serum uric acid levels prior to treatment initiation, and be closely monitored for TLS during and after treatment.</li> <li>Refer to UpToDate topics on tumor lysis syndrome.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1" rowspan="7"><strong>Gastrointestinal toxicity</strong></td> <td colspan="4"> <ul> <li>Doses of docetaxel and FU should be reduced for grade 3 or 4 diarrhea or mucositis:<sup>[2]</sup></li> </ul> </td> </tr> <tr> <td class="subtitle3">Toxicity</td> <td class="subtitle3" colspan="2">Dose adjustment</td> </tr> <tr> <td>Diarrhea grade 3</td> <td colspan="2">First episode: Reduce FU dose by 20%.<br/> Second episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td>Diarrhea grade 4</td> <td colspan="2">First episode: Reduce docetaxel and FU doses by 20%.<br/> Second episode: Discontinue treatment.</td> </tr> <tr> <td>Stomatitis/mucositis grade 3</td> <td colspan="2">First episode: Reduce FU dose by 20%.<br/> Second episode: Stop FU only at all subsequent cycles.<br/> Third episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td>Stomatitis/mucositis grade 4</td> <td colspan="2">First episode: Stop FU only at all subsequent cycles.<br/> Second episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td colspan="4"> <ul> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression or severe, prolonged neutropenia and/or thrombocytopenia after FU should prompt evaluation for DPD deficiency.</li> <li>Refer to UpToDate topics on enterotoxicity of chemotherapeutic agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Hepatotoxicity</strong></td> <td colspan="4"> <ul> <li>Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 times the ULN with AP &gt;2.5 times the ULN.<sup>[2]</sup> For intracycle increases of AST/ALT &gt;2.5 to ≤5 times the ULN and AP ≤2.5 times the ULN, <strong>or</strong> AST/ALT &gt;1.5 to ≤5 times the ULN <strong>and</strong> AP &gt;2.5 to ≤5 times the ULN, docetaxel should be reduced by 20%. In case of AST/ALT &gt;5 times the ULN <strong>and/or</strong> AP &gt;5 times the ULN, docetaxel should be stopped.<sup>[2]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents and chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="4"> <ul> <li>Patients should not be retreated with docetaxel until the neutrophil count is &gt;1500/microL.<sup>[2]</sup> In the original protocol, G-CSF was allowed during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than seven days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs, the United States Prescribing Information suggests reduction of docetaxel dose from 75 to 60 mg/m<sup>2</sup>. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced further from 60 mg/m<sup>2</sup> to 45 mg/m<sup>2</sup>. In case of grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup>.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Nephrotoxicity</strong></td> <td colspan="4"> <ul> <li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or BUN &lt;25 mg/dL. For grade ≥2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.</li> <li>Refer to UpToDate topics on cisplatin nephrotoxicity.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Neurologic toxicity</strong></td> <td colspan="4"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Reduce cisplatin dose 20% for grade 2 peripheral neuropathy and discontinue for grade 3 neuropathy or grade 3 ototoxicity.<sup>[2]</sup></li> <li>Refer to UpToDate topics on overview of neurologic complications of platinum-based chemotherapy.</li> <li>There is no recommended dose for resumption of FU administration following development of hyperammonemic encephalopathy, acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances; the drug should be permanently discontinued.<sup>[3]</sup></li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan="4"> <ul> <li>Hold FU for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[3]</sup></li> <li>Refer to UpToDate topics on cutaneous complications of conventional chemotherapy agents.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Cardiotoxicity</strong></td> <td colspan="4"> <ul> <li>Cardiotoxicity observed with FU includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. There is no recommended dose for resumption of FU administration following development of cardiac toxicity, and the drug should be discontinued.<sup>[3]</sup></li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="4"> <ul> <li>For other grade 3 or worse toxicity except for alopecia and anemia, delay chemotherapy (maximum of two weeks) until resolution to &lt;grade 1, then restart if medically appropriate.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="4"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes"><p>ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CBC: complete blood count; CYP3A4: cytochrome P450 3A4; DPD: dihydropyrimidine dehydrogenase; D5W: 5% dextrose in water; G-CSF: granulocyte-colony stimulating factors; IV: intravenous; TLS: tumor lysis syndrome; NS: normal saline; ULN: upper limit of normal.</p>
<p>* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).</p>
¶ A list of strong and moderate CYP3A4 inhibitors is available as a separate table in UpToDate. Specific interactions may be determined by use of the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included within UpToDate.</div><div class="graphic_reference">References:
<ol>
<li>Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Eng J Med 2007; 357:1695.</li>
<li>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on March 15, 2022).</li>
<li>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at <a href="https://dailymed.nlm.nih.gov" target="_blank">dailymed.nlm.nih.gov</a>, accessed on December 20, 2011).</li>
</ol></div><div id="graphicVersion">Graphic 72461 Version 27.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
